Lance D. Dworkin

TL;DR: An evidence-based approach is provided, integrating data from the major clinical trials that were designed as randomized prospective, long-term studies that had as a primary endpoint either progression of diabetic nephropathy or reduction in CV events to achieve lower blood pressure goals.

TL;DR: Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-arterY stenosis and hypertension or chronic kidney disease.

TL;DR: In this article, a Cox proportional-hazards regression analysis, unadjusted and individually adjusted for creatinine, albumin, and total cholesterol levels, total/HDL cholesterol ratio, dialysis adequacy/residual renal function, baseline CVD, and established CVD risk factors (ie, age, sex, smoking, hypertension, diabetes/glucose intolerance, and dyslipidemia) revealed that markedly elevated fasting total homocysteine (tHcy) levels found in dialysis-dependent ESRD patients may contribute independently to their

TL;DR: The presence of residual renal function, even at a low level, is associated with a lower mortality risk in HD patients, and was protective against mortality over a 2-year period.

TL;DR: A randomized clinical trial contrasting optimum medical therapy alone to stenting with optimum medical Therapy on a composite cardiovascular and renal end point and determining the incremental value of stent revascularization, in addition to optimal medical therapy, for the treatment of atherosclerotic renal artery stenosis.